Denali Therapeutics Inc. (DNLI)
2025-06-30 | 2024-09-30 | 2024-06-30 | ||
|---|---|---|---|---|
| Total collaboration revenue | - | - | - | |
| Research and development | 102,696,000 | 98,238,000 | 91,399,000 | |
| General and administrative | 32,267,000 | 24,949,000 | 25,194,000 | |
| Total operating expenses | 134,963,000 | 123,187,000 | 116,593,000 | |
| Gain from divestiture of small molecule programs | - | - | - | |
| Loss from operations | -134,963,000 | -123,187,000 | -116,593,000 | |
| Interest and other income, net | 10,844,000 | 15,995,000 | 17,567,000 | |
| Net loss | -124,119,000 | -107,192,000 | -99,026,000 | |
| Net unrealized loss on marketable securities, net of tax | -1,098,000 | 8,188,000 | -1,363,000 | |
| Comprehensive loss | -125,217,000 | -99,004,000 | -100,389,000 | |
| Net loss per share, basic (usd per share) | -0.72 | -0.63 | -0.59 | |
| Net loss per share, diluted (usd per share) | -0.72 | -0.63 | -0.59 | |
| Weighted average number of shares outstanding, basic (in shares) | 171,449,847 | 169,456,988 | 168,831,329 | |
| Weighted average number of shares outstanding, diluted (in shares) | 171,449,847 | 169,456,988 | 168,831,329 | |